Business Wire

ExaGrid Named a Finalist in SDC Awards 2019

30.10.2019 14:00:00 EET | Business Wire | Press release

Share

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been named a finalist in the Storage, Digitalisation + Cloud (SDC) Awards 2019. The SDC Awards – the new name for Angel Business Communications' IT awards – is firmly focused on recognizing and rewarding success in the products and services that are the foundation for digital transformation. ExaGrid’s EX Series backup storage appliances with data deduplication is nominated for “Backup Storage Innovation of the Year.” Voting to determine the winner in each category is underway now and closes on 15th November 2019 at 17:30 BST. The results will be revealed at an evening gala in London on 27th November 2019.

ExaGrid has gained the nomination due the EX Series’ uniquely scalable architecture and its specialized deduplication process. ExaGrid is best known for its industry-leading approach to backup storage with unique Landing Zone technology, Adaptive Deduplication approach, and cost-effective scale-out architecture. Managing data growth can cause strain on backup storage and ExaGrid set out to develop the best backup target possible. Through its intelligent hyperconverged storage for backup with data deduplication, ExaGrid helps IT organizations solve three of the most pressing issues they face today: how to protect and manage growing data, how to recover data as quickly as possible, and how to do so at a lower cost.

In data backup, organizations retain weekly, monthly and yearly backups in order to account for regulatory audits, legal discovery and other business reasons. It is not uncommon for organizations to retain 20 to 50 copies of their backup data at different historic points in time. As a result, the total backup storage can be 20 to 50 times greater than the initial primary storage copy. The cost of storage for backup becomes prohibitive and difficult to manage. The value that ExaGrid provides stems from its adaptive approach to deduplication, which offers a 20:1 data deduplication ratio. The ExaGrid system can easily scale to accommodate data growth. ExaGrid’s computing software makes the system highly scalable. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour, which is the highest in the industry. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic reducing IT staff maintenance and time.

The traditional inline approach to backup storage only stores deduplicated data. Therefore, both backups and restores are slow as data is deduplicated and rehydrated. As data grows, no additional compute resources are added – so the backup window grows until backups must be abandoned as they are cutting into production hours. Only an expensive, disruptive, forklift upgrade can resolve the longer backup windows. Instead, ExaGrid writes data straight to a disk Landing Zone for the fastest backups, while deduplication happens in parallel. The most recent backup is kept in undeduplicated form in its Landing Zone for the fastest restores and instant VM recovery, since no rehydration is necessary. Long-term retention data is stored deduplicated in the repository, which is a separate section of the appliance.

“ExaGrid’s nomination demonstrates the importance of innovation in the backup storage space and the need for a continued focus on data storage efficiency and cost savings,” said Bill Andrews, CEO and President of ExaGrid. “ExaGrid’s unique scale-out storage architecture provides all compute, network and storage resources for a fixed-length backup window as data grows. This provides essential time savings for strained IT staff. Our approach also eliminates expensive forklift upgrades and planned product obsolescence, which reduces the total cost of ownership for organizations looking to save storage space in their backup environment.”

ExaGrid supports all backup typologies including private cloud, offsite data center, third-party data center, third-party cloud, public cloud, and can operate in a pure hybrid environment.

Lastly, ExaGrid supports a wide variety of backup applications, utilities, and database dumps, such as Veeam, Commvault, Veritas NetBackup, IBM Spectrum Protect, HYCU, Zerto, Acronis and many others. ExaGrid allows multiple approaches within the same environment. An organization can use one backup application for its physical servers, a different backup application or utility for its virtual environment, and also perform direct Microsoft SQL or Oracle RMAN database dumps – all to the same ExaGrid system. This approach allows customers to use the backup application and utilities of their choosing, use best-of-breed backup applications and utilities, and choose the right backup application and utility for each specific use case. If the customer chooses to change their backup application in the future, the ExaGrid system will still work, protecting the initial investment.

About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique Landing Zone, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye